论文部分内容阅读
目的:分析淋巴瘤患者化疗继发糖尿病的发生率及相关因素,探索化疗继发糖尿病的危险因素。方法:对207例淋巴瘤化疗患者的年龄、性别、病理分型、临床分期、B症状、4~6个疗程化疗后评估是否完全反应等进行Logistic回归分析。结果:临床资料完整且符合条件的186例患者中,48例(25.8%)化疗后出现继发糖尿病。单因素分析显示,年龄≥40岁、有B症状、首次未完全反应为化疗继发糖尿病的危险因素。Logistic多因素回归分析结果显示,40岁以上患者发生继发糖尿病的风险是40岁以下患者的9.20倍(OR=9.200),有B症状是无B症状的2.90倍(OR=2.903),首次未完全反应是首次完全反应的2.08倍(OR=2.080)。结论:继发糖尿病是淋巴瘤患者化疗期间的重要并发症,发生率为25.8%,年龄≥40岁、有B症状、首次未完全反应为化疗继发糖尿病的独立危险因素。
Objective: To analyze the incidence of secondary diabetes mellitus in patients with lymphoma and related factors, and explore the risk factors of secondary diabetes mellitus. Methods: Logistic regression analysis was performed on the age, sex, pathological type, clinical stage, symptoms of B, and the complete response after 4 ~ 6 cycles of chemotherapy in 207 patients with lymphoma. Results: Of the 186 patients with complete and eligible clinical data, 48 (25.8%) had secondary diabetes after chemotherapy. Univariate analysis showed that the age of 40 years old, B symptoms, for the first time did not fully respond to chemotherapy for secondary diabetes risk factors. Logistic multivariate regression analysis showed that the risk of secondary diabetes in patients older than 40 years was 9.20 times higher than those under 40 years old (OR = 9.200), 2.90 times higher than those without B symptoms (OR = 2.903), the first time without The complete response was 2.08 times the first complete response (OR = 2.080). Conclusion: Secondary diabetes is an important complication of chemotherapy in patients with lymphoma, the incidence rate was 25.8%, age ≥ 40 years old, with symptoms of B, the first incomplete response was an independent risk factor for chemotherapy-induced secondary diabetes.